TC Biopharm (Holdings) Past Earnings Performance
Past criteria checks 0/6
TC Biopharm (Holdings) has been growing earnings at an average annual rate of 18.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 2.4% per year.
Key information
18.5%
Earnings growth rate
44.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -2.4% |
| Return on equity | -220.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How TC Biopharm (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -6 | 7 | 7 |
| 30 Sep 23 | 1 | -4 | 7 | 7 |
| 30 Jun 23 | 3 | -2 | 7 | 8 |
| 31 Mar 23 | 3 | -1 | 8 | 8 |
| 31 Dec 22 | 4 | -1 | 9 | 7 |
| 30 Sep 22 | 3 | -4 | 8 | 7 |
| 30 Jun 22 | 2 | -10 | 7 | 7 |
| 31 Mar 22 | 2 | -12 | 5 | 7 |
| 31 Dec 21 | 2 | -14 | 3 | 6 |
| 30 Sep 21 | 2 | -11 | 2 | 6 |
| 30 Jun 21 | 2 | -5 | 2 | 6 |
| 31 Mar 21 | 2 | -5 | 2 | 6 |
| 31 Dec 20 | 2 | -5 | 2 | 7 |
| 31 Dec 19 | 3 | -6 | 3 | 9 |
Quality Earnings: TCBP is currently unprofitable.
Growing Profit Margin: TCBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCBP is unprofitable, but has reduced losses over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare TCBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: TCBP has a negative Return on Equity (-219.98%), as it is currently unprofitable.